logo
  

GSK : FDA Approves Mepolizumab For Use In Adults With Chronic Rhinosinusitis With Nasal Polyps

GlaxoSmithKline plc (GSK,GSK.L) said that the US Food and Drug Administration has approved Nucala or mepolizumab, a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps or CRSwNP.

The new indication for mepolizumab is for the add-on maintenance treatment of CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

Mepolizumab is the first anti-IL-5 biologic to be approved for adult patients with CRSwNP in the US. It is the Fourth indication for mepolizumab in the US for eosinophil-driven diseases.

Mepolizumab is also approved for use in three other eosinophilic driven diseases, the first indication being for patients with severe eosinophilic asthma aged six years and older. Additionally, mepolizumab was the first biologic therapy indicated for adults with eosinophilic granulomatosis with polyangiitis and also the first biologic to be approved for patients aged 12 years and older with hypereosinophilic syndrome.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple announced that Apple News will be extending its local news offering to three additional cities in the United States to offer local news experience to readers. The service will now be provided for Charlotte, Miami, and Washington, D.C. The local news experience for each city is curated by Apple News editors to provide coverage of topics of importance for local communities. Automaker General Motors Co. (GM) on Wednesday reported third-quarter net income attributable to shareholders of $2.42 billion or $1.62 per share, lower than $4.05 billion or $2.78 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $1.52 per share, compared... Boeing on Wednesday reported a loss for the first quarter that sharply narrowed from last year, reflecting an 8 percent increase in revenues on higher commercial airplanes and services volumes. However, core loss per share and quarterly revenues came in below analysts' expectations. Looking ahead, the airplane maker said supply chain capacity and global trade will be key drivers of the industry.
Follow RTT